Warner-Lambert's Cognex
Executive Summary
FDA's Peripheral/CNS Drugs Advisory Committee will review Cognex (tacrine) NDA on March 15 beginning at 8:30 a.m. at the Crowne Plaza Holiday Inn, Rockville, MD. The Alzheimer's drug was classified by FDA as a "1A" drug (representing a significant therapeutic gain over existing therapies) late last year.